Tumor glycolytic profiling through 18 F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC.
Saulo Brito SilvaCarlos Wagner S WanderleyJosé Flávio G MarinMariana Petaccia de MacedoEllen Caroline Toledo do NascimentoFernanda Frozoni AntonacioCaroline Sales FigueiredoMateus Trinconi CunhaFernando de Queiroz CunhaGilberto de Castro JuniorPublished in: Therapeutic advances in medical oncology (2022)
F-FDG PET/CT are useful biomarkers for evaluating ICI therapy in advanced NSCLC.